Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Private Placement closes

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 15, 2023 1:49pm

90 Views

Post# 35340459

RE:RE:Private Placement closes

Yes ToniZ1 the operative word is hope. The device at this point works but as far as i can surmise they need to produce a production line model to be tested for FDA approval. At the moment they only have a hand built version which does not qualify for FDA testing.
Yes, I am hopeful we eventually see the device submitted for approval but the big question is when. To my mind it is not soon unfortunately.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?